Increased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels
Abstract
Background: Given the difficult clinical differential diagnosis between Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), growing interest resulted in research on α‐synuclein as a potential cerebrospinal fluid biomarker (CSF) for synucleinopathies. Methods: CSF α‐synuclein‐140 concentrations were determined by a prototype xMAP™ bead‐based assay (Innogenetics NV, Belgium). In addition, CSF amyloid β 1‐42 (Aβ 1‐42), total tau (T‐tau), and phosphorylated tau (P‐tau 181P) levels were determined. Results: CSF α‐synuclein levels were higher in AD patients as compared with cognitively healthy controls (P = .019) and patients with synucleinopathies (P < .001). CSF α‐synuclein levels were correlated with T‐tau (P < .001) and P‐tau 181P (P < .001) levels in autopsy‐confirmed AD patients. A diagnostic algorithm using α‐synuclein and P‐tau 181P discriminated neuropathologically confirmed AD from DLB patients, resulting in sensitivity and specificity values of 85% and 81%, respectively. Conclusion: Because CSF α‐synuclein levels were significantly higher in AD as compared with synucleinopathies, α‐synuclein might have a value as a biomarker for differential dementia diagnosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Numerous studies have documented unaltered or slightly increased cerebrospinal fluid αSyn levels in patients with mild cognitive impairment and Alzheimer's disease.
“numerous studies have documented unaltered or slightly increased CSF αSyn levels in patients with MCI and AD [27, 80–82, 86, 90, 91, 93, 94].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [90]
Cites
1 retracted
RETRACTED: Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology
Larson, M. E., Sherman, M. A., Greimel, S., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0581-12.2012 · Cited by 128 · see citing works
RetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · see citing works
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · see citing works
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · see citing works
2013 Alzheimer's disease facts and figures
Thies, W. H., & Bleiler, L. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,331 · see citing works
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · see citing works
Second consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140 · see citing works
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works
Merritt, H. H., FREMONT-SMITH, F., & Ayer, J. B. (1938) · The American Journal of the Medical Sciences · doi:10.1097/00000441-193804000-00024 · Cited by 876 · see citing works
McKeith, I. G. (2004) · Europe PMC (PubMed Central) · Cited by 756 · see citing works
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 702 · see citing works
DSM‐IV‐TR: Diagnostic and Statistical Manual of Mental Disorders
Chao, R., & Manita, J. (2013) · The Encyclopedia of Cross‐Cultural Psychology · doi:10.1002/9781118339893.wbeccp180 · Cited by 683 · see citing works
Spira, P. J., Sharpe, D. M., Halliday, G. M., Cavanagh, J., & Nicholson, G. A. (2001) · Annals of Neurology · doi:10.1002/ana.67 · Cited by 628 · see citing works
Mollenhauer, B., Locascio, J. J., Schulz‐Schaeffer, W., Sixel‐Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 623 · see citing works
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615 · see citing works
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El‐Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 526 · see citing works
Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473 · see citing works
Self-citationTokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425 · see citing works
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
Shi, M. Y., Bradner, J. M., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J. J., Zabetian, C. P., Kim, H. M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 418 · see citing works
Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382 · see citing works
Spira, P. J., Sharpe, D. M., Halliday, G. M., Cavanagh, J., & Nicholson, G. A. (2001) · PubMed · Cited by 343 · see citing works
Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies
Merdes, A., Hansen, L. A., Jeste, D. V., Galasko, D. R., Hofstetter, C. R., Ho, G. J., Thal, L. J., & Corey‐Bloom, J. (2003) · Neurology · doi:10.1212/01.wnl.0000065889.42856.f2 · Cited by 320 · see citing works
Phosphorylated α-Synuclein in Parkinson’s Disease
Wang, Y., Shi, M. Y., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M. ‐., Siderowf, A. D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002566 · Cited by 281 · see citing works
Hansson, O., Zetterberg, H., Vanmechelen, E., Vanderstichele, H., Andréasson, U., Londos, E., Wallin, A., Minthon, L., & Blennow, K. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.027 · Cited by 276 · see citing works
Self-citationLow sensitivity in clinical diagnoses of dementia with Lewy bodies
Nelson, P. T., Jicha, G. A., Kryscio, R. J., Abner, E. L., Schmitt, F. A., Cooper, G. E., Xu, L., Smith, C. D., & Markesbery, W. R. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5324-y · Cited by 273 · see citing works
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
Engelborghs, S., de Vreese, K., de Casteele, T. V., Vanderstichele, H., Everbroeck, B. V., Cras, P. P., Martin, J., Vanmechelen, E., & Deyn, P. P. D. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.016 · Cited by 256 · see citing works
Self-citationAnalytical error and interference in immunoassay: minimizing risk
Sturgeon, C. M., & Viljoen, A. (2011) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011073 · Cited by 230 · see citing works
Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?
Öhrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., & Zetterberg, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.015 · Cited by 198 · see citing works
Self-citationCerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias
Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., Carlo, C. D., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., et al. (2011) · Movement Disorders · doi:10.1002/mds.23670 · Cited by 170 · see citing works
Alternative α-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology
Rhinn, H., Qiang, L., Yamashita, T., Rhee, D. B., Zolin, A., Vanti, W. B., & Abeliovich, A. (2012) · Nature Communications · doi:10.1038/ncomms2032 · Cited by 142 · see citing works
Kasuga, K., Tokutake, T., Ishikawa, A., Uchiyama, T., Tokuda, T., Onodera, O., Nishizawa, M., & Ikeuchi, T. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.197483 · Cited by 142 · see citing works
Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., Hansson, O., & Nielsen, H. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053250 · Cited by 141 · see citing works
CSF α-synuclein does not differentiate between parkinsonian disorders
Aerts, M., Esselink, R. A. J., Abdo, W. F., Bloem, B. R., & Verbeek, M. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.001 · Cited by 126 · see citing works
Tateno, F., Sakakibara, R., Kawai, T., Kishi, M., & Murano, T. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31823899cc · Cited by 121 · see citing works
Engelborghs, S., Sleegers, K., Cras, P. P., Brouwers, N., Serneels, S., Leenheir, E. D., Martin, J. J., Vanmechelen, E., Broeckhoven, C. V., & Deyn, P. P. D. (2007) · Brain · doi:10.1093/brain/awm136 · Cited by 113 · see citing works
Self-citationToledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., & Zhang, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1148-z · Cited by 106 · see citing works
Altered CSF Orexin and α-Synuclein Levels in Dementia Patients
Wennström, M., Londos, E., Minthon, L., & Nielsen, H. M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111655 · Cited by 104 · see citing works
α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment
Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95 · see citing works
Cerebrospinal Fluid α-Synuclein Does Not Discriminate Between Dementia Disorders
Spies, P. E., Melis, R. J. F., Sjögren, M. J. C., Rikkert, M. G. M. O., & Verbeek, M. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0955 · Cited by 93 · see citing works
CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease
Noguchi‐Shinohara, M., Tokuda, T., Yoshita, M., Kasai, T., Ono, K., Nakagawa, M., El‐Agnaf, O. M. A., & Yamada, M. (2008) · Brain Research · doi:10.1016/j.brainres.2008.11.055 · Cited by 92 · see citing works
CSF α-Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease
Reesink, F. E., Lemstra, A. W., van Dijk, K. D., Berendse, H. W., van de Berg, W. D. J., Klein, M., Blankenstein, M. A., Scheltens, P., Verbeek, M. M., & van der Flier, W. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100186 · Cited by 84 · see citing works
Phosphorylated alpha-Synuclein in Parkinson's Disease
Wang, Y., Shi, M., Chung, K. A., et al. (2012) · Science Translational Medicine · Cited by 76 · see citing works
Added diagnostic value of CSF biomarkers in differential dementia diagnosis
Bastard, N. L., Martin, J., Vanmechelen, E., Vanderstichele, H., Deyn, P. P. D., & Engelborghs, S. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.10.017 · Cited by 67 · see citing works
Self-citationInterference from Heterophilic Antibodies in Amyloid-β Oligomer ELISAs
Sehlin, D., Söllvander, S., Paulie, S., Brundin, R., Ingelsson, M., Lannfelt, L., Pettersson, F. E., & Englund, H. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100609 · Cited by 58 · see citing works
Su, E. R., Bell, M. J., Wisniewski, S. R., Adelson, P. D., Janesko‐Feldman, K. L., Salonia, R., Clark, R. S. B., Kochanek, P. M., Kagan, V. E., & Bayır, H. (2010) · Developmental Neuroscience · doi:10.1159/000321342 · Cited by 55 · see citing works
Amyloid Pathology Influences Aβ1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies
Slaets, S., Bastard, N. L., Theuns, J., Sleegers, K., Verstraeten, A., Leenheir, E. D., Luyckx, J., Martin, J., Broeckhoven, C. V., & Engelborghs, S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122176 · Cited by 54 · see citing works
Self-citationBeyer, K., Domingo-Sàbat, M., dos Santos, C. M. P., TOLOSA, E. S., Ferrer, I., & Ariza, A. (2010) · Brain · doi:10.1093/brain/awq275 · Cited by 41 · see citing works
Wang, H., Wang, K. Y., Xu, W., et al. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07749.x · Cited by 31 · see citing works
Goodrum (2000) · doi:10.1002/(sici)1097-4547(20000215)59:4
Flagged first, then by citations
Cited by
Sorted by citations
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374 · see citing works
Vergallo, A., Bun, R., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Cavedo, E., Lamari, F., Habert, M., Dubois, B., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3053 · Cited by 59 · see citing works
Majbour, N. K., Chiasserini, D., Vaikath, N. N., Eusebi, P., Tokuda, T., van de Berg, W., Parnetti, L., Calabresi, P., & El-Agnaf, O. M. A. (2017) · Scientific Reports · doi:10.1038/srep40263 · Cited by 55 · see citing works
- Authors
- Slaets, S., Vanmechelen, E., Le Bastard, N., Decraemer, H., Vandijck, M., Martin, J., De Deyn, P. P., & Engelborghs, S.
- Affiliations
- University of Antwerp (BE)
- Fujirebio (Belgium) (BE)
- Reference Center for Biological Markers of Dementia (BIODEM) Laboratory of Neurochemistry and Behavior Institute Born‐Bunge University of Antwerp Antwerp Belgium
- Corresponding author
- Engelborghs, Sebastiaan
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-01-17
- Volume
- 10
- Issue
- 5S
- Pages
- S290-8
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W1966449557
- Cited by
- 85
- References
- 51
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 13 · 2019: 7 · 2018: 11 · 2017: 7 · 2016: 8 · 2015: 5 · 2014: 4
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- University Research Fund of the University of Antwerp
- Foundation for Alzheimer Research
- Institute Born-Bunge
- Central Biobank Facility of the Institute Born-Bunge/University Antwerp
- Janssen
- Neurosearch Antwerp
- Research Foundation– Flanders
- Interuniversity Attraction Poles
- Flemish Government
- Medical Research Foundation Antwerp
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- alpha-synuclein, cerebrospinal fluid biomarkers
- MeSH terms
- Aged, Algorithms, Alzheimer Disease, Female, Humans, Male, Peptide Fragments, Phosphorylation, Sensitivity and Specificity, Biomarkers, Amyloid beta-Peptides, tau Proteins, Lewy Body Disease, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
